Sun Pharmaceutical Industries, Inc. announced the FDA approval of its ANDA for levophenanol tartrate oral tablets, following the loss of patents protecting the previous brand. This approval allows the pharma giant to enter the market with a potentially more affordable therapeutic alternative during a period when the industry faces intensifying competition and pressure on classic blockbuster cash flows.